language
News
06-19
2024
The innovative drug HZ-H08905 tablets of Hangzhou HealZen Therapeutics Co., Ltd has been approved for a pivotal Phase III clinical trial for the treatment of recurrent or refractory peripheral T-cell lymphoma
Hangzhou HealZen Therapeutics Co., Ltd recently announced that its independently developed Class 1 innovative drug, HZ-H08905 (CK1ε&PI3Kδ dual-target inhibitor), has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China, to conduct a pivotal registration Phase III clinical trial for the treatment of recurrent or refractory peripheral T-cell lymphoma (R/R PTCL).
HealZen Therapeutics Co., Ltd.
Telephone: +86-571-86933001
E-mail: info@healzentx.com
Address: 8th Floor, Building 16, Hexiang Science and Technology Center, Qiantang District, Hangzhou City, P.R.China
Copyright © HealZen Therapeutics Co., Ltd. Powered by www.300.cn